Eupraxia Pharmaceuticals to Present at CRS 2024 Annual Meeting

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company based in Victoria, BC, has announced that its Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the Controlled Release Society 2024 Annual Meeting and Expo in Bologna, Italy. The event will take place from July 8-12, 2024.

Eupraxia Pharmaceuticals is dedicated to the development of locally delivered, extended-release products designed to meet critical therapeutic needs. The company's innovative technology, DiffuSphere™, leverages polymer-based micro-spheres to deliver drugs in a targeted manner with prolonged effects and minimized side effects. This technology is adaptable for various active pharmaceutical ingredients and delivery methods, offering multiple pharmacokinetic profiles that can be finely tuned.

The company's flagship product, EP-104GI, is currently undergoing a Phase 1b/2a trial named the RESOLVE trial for the treatment of eosinophilic esophagitis (EoE). This condition involves chronic inflammation of the esophagus, and Eupraxia's approach involves injecting the drug directly into the esophageal wall for localized effect. This method is considered unique in the treatment landscape for EoE.

Furthermore, the company recently concluded a Phase 2b clinical trial named SPRINGBOARD, which evaluated EP-104IAR for treating osteoarthritis pain in the knee. This trial successfully met its primary endpoint and three out of four secondary endpoints, indicating promising results for the product's efficacy and safety.

Eupraxia is also developing a range of other long-acting formulations in early and later stages of development. These formulations target various therapeutic areas, including other inflammatory joint conditions and oncology. The goal is to enhance the activity and tolerability of existing drugs.

Dr. Amanda Malone's presentation at the Controlled Release Society Annual Meeting and Expo will shed light on Eupraxia's advancements and the potential of their DiffuSphere™ technology in optimizing drug delivery. This event provides an excellent platform for the company to showcase its research and development efforts to a broader scientific community.

Eupraxia Pharmaceuticals remains committed to addressing unmet medical needs through innovative drug delivery systems that offer improved patient benefits, such as prolonged activity and reduced side effects. With ongoing trials and a robust development pipeline, the company is positioned to make significant contributions to the field of biotechnology and therapeutic treatments.